Schedule 13G ownership disclosure

CytomX Therapeutics Inc

Common Stock, $0.00001 par value per share · CUSIP: 23284F105

Event date: 2025-05-13

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Longitude Capital Partners V, LLC

    Shares: 11,538,461 · Class: 7.3%

  • Longitude Venture Partners V, L.P.

    Shares: 11,538,461 · Class: 7.3%

  • Patrick G. Enright

    Shares: 11,538,461 · Class: 7.3%

  • Juliet Tammenoms Bakker

    Shares: 11,538,461 · Class: 7.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000950170-25-075515
Form type
SCHEDULE 13G
Filer
CytomX Therapeutics, Inc.
CIK
CIK 1501989
Filed
May 20, 2025
Reporting period
May 13, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub